U.S. Early Toxicity Testing Market

Plastic Optic Fiber Market Report Thumbnail

U.S. Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemical Industry, Food Industry, and Others) – Opportunity Analysis and Industry Forecast, 2023-2030

Industry: Healthcare | Publish Date: 23-Aug-2023 | No of Pages: 93 | No. of Tables: 83 | No. of Figures: 32 | Format: PDF | Report Code : N/A

  • Facebook
  • Linkedin
  • Whatsapp

Market Definition

The U.S. Early Toxicity Testing Market was valued at USD 2.42 billion in 2022, and is predicted to reach USD 4.14 billion by 2030, with a CAGR of 6.02% from 2023 to 2030.

Early toxicity testing is a fundamental procedure encompassing the evaluation of potential toxicity or detrimental impacts arising from drugs, chemicals, or various substances during their preliminary developmental phases. This assessment predominantly occurs through in vitro studies or animal models before human trials commence.

The overarching objective of early toxicity testing is to promptly uncover any safety-related apprehensions linked to a substance, thus facilitating informed decisions about its feasibility for continued development and subsequent testing. 

By conducting early toxicity testing, the risks of adverse effects on both human subjects and animals during clinical trials are mitigated, simultaneously curtailing expenses and time invested in the overall drug development trajectory. This intricate process encompasses a gamut of examinations and assays, encompassing cell viability assessments, genotoxicity evaluations, and pharmacokinetic investigations.

The specific modalities employed are contingent on the intrinsic nature of the substance under scrutiny and its intended application. Recognized as an indispensable phase within the drug development journey, early toxicity testing profoundly bolsters the assurance of safety and efficacy for novel drugs and other substances, prior to their regulatory endorsement for human utilization.

Robust Healthcare Infrastructure and Cardiovascular Disease Prevalence in the U.S. is Driving the Market Growth

The early toxicity testing market is growing, owing to robust healthcare infrastructure, high investment in R&D, and increase in demand for high-quality pharmaceutical products in the U.S.

For instance, according to the Centers for Medicare & Medicaid Services, the national healthcare expenditure reached 4.3 trillion in 2021 in the United States. In addition, the market is being driven by rise in prevalence of heart diseases, which is a leading cause of death in the U.S. and has been on the rise in recent years.

For instance, according to the Centers for Disease Control and Prevention (CDC), around 697,000 Americans died from heart disease in 2020, which is approximately 1 in every 5 deaths.

 

The Escalated Demand for High-quality Pharmaceuticals in the U.S. Propels Increased Investment in Early Toxicity Testing

In the dynamic landscape of healthcare, a notable paradigm shift has taken root within the United States, which resulted a transformation fuelled by the ever-increasing expectations of the population for pharmaceutical solutions that transcend mere functionality. This transformative trend centers around the resolute pursuit of high-quality, potent, and dependable pharmaceutical products that not only meet medical needs but also resonate with the deep-seated desire for safety and efficacy.

This palpable shift in consumer aspirations is serving as a transformative force, compelling pharmaceutical enterprises to recalibrate their strategies and invest more assertively in early toxicity testing. In essence, this strategic investment serves as the bedrock upon which the safety and reliability of pharmaceutical products are firmly anchored, thereby fostering a marked expansion of the early toxicity testing market in U.S.

 

Regulatory Constraints and their Impact on Early Toxicity Testing Market Growth in U.S.

However, stringent regulations set by regulatory bodies such as the US FDA and the EMA require extensive and rigorous testing for drug development and safety, which can be time-consuming and expensive and restrain growth of the market. The complexity and cost of complying with these regulations can pose a significant challenge for small and medium-sized companies that may not have the resources to carry out extensive testing.

As a result, some companies may choose to delay or abandon drug development projects, which can limit demand for early toxicity testing services. Moreover, stringent regulations can also result in a lengthy approval process for new drugs, further delaying the time it takes for drugs to reach the market. This, in turn, is expected to hamper growth of the market.

Technological Advancements in the field of Early Toxicity Testing Market in U.S.

Introduction of new technologies such as in-vitro modelling using 3D cell culture is expected to provide new lucrative opportunities for the early toxicity testing market during the forecast period.

Use of 3D cell cultures can better mimic complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. Traditional 2D cell culture models are limited in their ability to mimic complexity of human tissues and organs, often leading to inaccurate and unreliable results in toxicity testing.

However, use of 3D cell culture models can better mimic structural and functional complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. 3D cell cultures allow growth and interaction of multiple cell types, creating a microenvironment that more closely resembles human tissues and organs. This can better predict toxic effects of drugs and chemicals in the human body, reducing the risk of adverse effects in clinical trials. Hence, such factors propel the market growth.

 

Competitive Landscape  

The U.S. Early Toxicity Testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG., and Thermo Fisher Scientific Inc.

KEY BENEFITS

  • The U.S. Early Toxicity Testing market report provides a quantitative analysis of the current market and estimations through 2023-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the market trend including the current and future trends for depicting the prevalent investment pockets in the industry.

  • The information related to key drivers, restraints, and opportunities and their impact on the market is provided in the report.

  • The competitive analysis of the key players along with their market share in the U.S. Early Toxicity Testing market.

  • The SWOT analysis and Porter’s Five Forces model are elaborated in the study.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

U.S. EARLY TOXICITY TESTING MARKET KEY SEGMENTS

By Technique

  • In Vivo

  • In Vitro

    • Cell Culture    

    • PCR    

    • ELISA    

    • Western Blotting    

    • Protein Binding Assays    

  • In Silico    

By Toxicity Endpoint

  • Genotoxicity    

  • Dermal Toxicity 

  • Skin Toxicity 

  • Ocular Toxicity    

  • Phototoxicity    

  • Others    

By End User

  • Pharmaceutical Industry    

  • Cosmetic Industry    

  • Chemical Industry    

  • Food Industry     

  • Others

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2022

USD 2.42 Billion

Revenue Forecast in 2030

USD 4.14 Billion

Growth Rate

CAGR of 6.02% from 2023 to 2030

Analysis Period

2022–2030

Base Year Considered

2022

Forecast Period

2023–2030

Market Size Estimation

Billion (USD)

Growth Factors

Healthcare infrastructure and cardiovascular disease prevalence.

 

Demand for quality pharmaceuticals.

Companies Profiled

15

Market Share

Available for 15 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

KEY PLAYERS

  • Inotiv Inc.

  • Bio-Rad Laboratories Inc

  • Evotec A.G. 

  • Agilent Technologies Inc

  • Wuxi Apptec

  • Bruker

  • Perkinelmer Inc.

  • Enzo Biochem Inc.

  • Danaher Corporation

  • Eurofins Scientific SE

  • Charles River Laboratories International, Inc.

  • Labcorp Drug Development.

  • Promega Corporation

  • Insphero AG

  • Thermo Fisher Scientific Inc.

Bar chart Pie chart Pie chart

Frequently Asked Questions

According to the report published by the Next Move Consulting, the U.S. early toxicity testing market business is expected to hit at $4.14 billion (USD) by 2030.

The U.S. early toxicity testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG, and Thermo Fisher Scientific Inc.

The U.S. early toxicity testing market share is segmented on the basis of technique, toxicity endpoint, and end user.

The factors driving the growth of the U.S. early toxicity testing market are healthcare infrastructure and cardiovascular disease prevalence, demand for quality pharmaceuticals, and technological advancements.

The factors limiting the growth of the U.S. early toxicity testing market are stringent regulatory compliance and high initial costs.

Download Free Sample

Please Enter Full Name

Please Enter Valid Email ID

Please enter Country Code and Phone No

Please enter message

popular
$2,575
$1,575
$3,875
$2,975

This website uses cookies to ensure you get the best experience on our website. Learn more